Cumulative sales of Daiichi Sankyo’s HER2-positive breast cancer treatment ‘Enhertu (trastuzumab-deruxtecan)’ have exceeded KRW 10 billion even without reimbursement.

According to the market research institution IQVIA on the 27th, Enhertu's cumulative sales were KRW 13.8 billion by Q3 this year. Sales steadily increased from KRW 2.2 billion in Q1, to KRW 5.2 billion in Q2, then to 6.4 billion in Q3 this year.

In other words, the drug has posted cumulative sales of more than KRW 10 billion without insurance reimbursement. The non-reimbursed administration cost of Enhertu is known to be around KRW 7 million for each cycle that consists of 3 doses. For patients who participate in the com